

This Week's **Top** Industry News

Provided as a service to DCAT member companies each Friday.

BUSY WEEK? Here are the **TOP INDUSTRY NEWS** stories you might have missed, as selected by DCAT Editorial Director *Patricia Van Arnum*.

1. [Gilead Sciences, Galapagos Close \\$2 Billion Deal for Anti-Inflammatory Drug](#)

Gilead Sciences and Galapagos NV, a Belgian biopharmaceutical company, have closed their previously announced \$2 billion global license and collaboration agreement for the JAK1-selective inhibitor, filgotinib, for treating inflammatory disease indications. [Read More](#)

2. [J&J Restructures Medical Device Business](#)

Johnson & Johnson has announced restructuring actions in its medical devices businesses for which the company will take charges of approximately \$2.0 billion to \$2.4 billion and reduce its global medical device workforce by 4% to 6%. [Read More](#)

3. [Samsung and Biogen JV Get EU OK for Biosimilar of Enbrel](#)

Samsung Bioepis, a joint venture between Biogen and Samsung BioLogics, has been granted European Commission approval for Benepali, an etanercept biosimilar referencing Enbrel, the first such biosimilar in the European Union. [Read More](#)

4. [Bayer Opens OTC Manufacturing Facility in China](#)

Bayer has opened its manufacturing site of traditional Chinese medicine and Western medicines in Yunnan, China. The site is Bayer's second largest over-the-counter manufacturing facility in Asia Pacific. [Read More](#)

5. [Pfizer Acquires OTC Company in China](#)

Pfizer has acquired Treerly Health Co., Ltd., a Chinese company specializing in women's nutritional products, and will continue a supply pact with Treerly's parent company, Sirio Pharma, a privately held contract manufacturing company in China. [Read More](#)

6. [Pharma Industry, Governments Partner For Developing New Antibiotics](#)

More than 80 pharmaceutical, generics, diagnostics and biotechnology companies, as well as key industry bodies, have signed the Declaration on Combating Antimicrobial Resistance at the World Economic Forum in Davos, Switzerland, setting a path for facilitating the development of new antibiotics to combat drug-resistant infections. [Read More](#)

7. [FDA OKs Novartis' Cosentyx for Two New Uses](#)

The FDA has approved Novartis' Cosentyx (secukinumab), a drug positioned as a potential blockbuster, for two new indications, active ankylosing spondylitis and active psoriatic arthritis. [Read More](#)

8. [J&J Expands South African Manufacturing Facility](#)

Johnson & Johnson has opened its newly refurbished ZAR 300 million (\$18 million) pharmaceutical manufacturing plant in Cape Town, South Africa. [Read More](#)

9. [GE Healthcare Invests in Cell Technologies Center](#)

GE Healthcare, the Federal Economic Development Agency for Southern Ontario, and the Center for Commercialization of Regenerative Medicine are building a center for advanced therapeutic cell technologies in Toronto with an investment of CAD \$40 million (\$28 million). [Read More](#)

10. [iBio Launches New Biologics CMO](#)

iBio, Inc., a biotechnology company specializing in developing and manufacturing plant-based biological products, has formed a joint venture with affiliates of Eastern Capital Limited to launch iBio CMO, a new biologics contract manufacturing organization. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599

www.dcat.org

[Forward this email](#)



This email was sent to esanders@dcat.org by dcatnews@dcat.org | [Update Profile/Email Address](#) | Rapid removal with [SafeUnsubscribe™](#) | [About our service provider.](#)

Drug, Chemical, & Associated Technologies Association | One Union Street | Suite 208 | Robbinsville | NJ | 08691